Oncology Candidates Stream From Exelixis Discovery Platform
Firm will decide whether - and how - to advance three late Phase I compounds in 2009; next big deal likely to focus on PI3/mTOR inhibitors.
Firm will decide whether - and how - to advance three late Phase I compounds in 2009; next big deal likely to focus on PI3/mTOR inhibitors.